Gastroenterology

Gastroenterology

Volume 121, Issue 5, November 2001, Pages 1185-1190
Gastroenterology

Basic Research
Hepatic uptake of cholecystokinin octapeptide by organic anion-transporting polypeptides OATP4 and OATP8 of rat and human liver,☆☆

https://doi.org/10.1053/gast.2001.28704Get rights and content

Abstract

Background & Aims: Cholecystokinin (CCK) is a major gastrointestinal peptide hormone that is released postprandially from the small intestine and exerts marked effects on gallbladder and gastrointestinal motility. The smaller isoforms CCK-8 and CCK-4 are rapidly taken up into hepatocytes, metabolized, and excreted into bile. Our aim was to identify and characterize the hepatocellular CCK-8 uptake system. Methods: CCK-8 uptake was measured in Xenopus laevis oocytes expressing the organic anion-transporting polypeptides of rat liver (Oatp1, Oatp2, Oatp3, or Oatp4) and of human liver (OATP-A, OATP-B, OATP-C, or OATP8) and in primary cultured rat hepatocytes. Results: Rat Oatp4 and human OATP8 efficiently mediated CCK-8 uptake in oocytes, with Michaelis constant (Km) values of 14.9 ± 2.9 μmol/L and 11.1 ± 2.9 μmol/L, respectively. CCK-8 uptake by hepatocytes was also saturable, with a Km of 6.7 ± 2.1 μmol/L. The Km value in rat hepatocytes is consistent with Oatp4-mediated transport. Conclusions: CCK-8 is selectively transported by rat Oatp4 and human OATP8, both of which are exclusively expressed at the basolateral membrane of hepatocytes. These 2 transporters are the first and probably the predominant hepatic uptake systems for CCK-8 and may be critical for the rapid clearance of this hormone from the circulation.

GASTROENTEROLOGY 2001;121:1185-1190

Section snippets

Materials

Radiolabeled [3H]CCK-8 (69-74 Ci/mmol) was obtained from Amersham Pharmacia Biotech (Buckinghamshire, England). Collagenase type 2 CLS was from Worthington Biochemical Corp. (Freehold, NJ). All other chemicals were of the highest degree of purity available and were readily available from commercial sources.

Uptake studies in xenopus laevis oocytes

Capped Oatp/OATP complementary RNA (cRNA) was synthesized in vitro using the mMESSAGE mMACHINE T7 kit (Ambion, Austin, TX) as previously described.21X. laevis oocytes were prepared as

Results

We initially tested transport of [3H]CCK-8 by the known Oatps of rat liver. Three days after injection of cRNA into X. laevis oocytes, the liver-specific Oatp4 (Slc21a6) efficiently mediated CCK-8 transport (25-fold stimulation of uptake compared with water-injected oocytes), whereas oocytes expressing Oatp1 (Slc21a1), Oatp2 (Slc21a5), or Oatp3 (Slc21a7) did not show any measurable uptake (Figure 1A).

. Comparison of CCK-8 uptake by X. laevis oocytes expressing either (A) rat Oatps or (B) human

Discussion

Over the past 2 decades, increasing evidence has suggested carrier-mediated hepatic uptake of the gastrointestinal peptide hormone CCK-8, including (1) a concentration gradient for this hormone between the portal and the systemic venous circulation;30 (2) reduced biologic activity of CCK-8 after intraportal administration compared with systemic administration;31 (3) elevated CCK-8 plasma levels in patients with liver cirrhosis;32 (4) rapid appearance of radiolabeled CCK-8 in the liver after

Acknowledgements

The authors thank Monika Gersbach-Fey for expert technical assistance.

References (34)

  • Y Cui et al.

    Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6

    J Biol Chem

    (2001)
  • V Mutt

    Cholecystokinin: isolation, structure, and functions

  • RA Liddle et al.

    Regulation of gastric emptying in humans by cholecystokinin

    J Clin Invest

    (1986)
  • HT Debas et al.

    Pure cholecystokinin: pancreatic protein and bicarbonate response

    Digestion

    (1973)
  • GJ Dockray

    The action of gastrin and cholecystokinin-related peptides on pancreatic secretion in the rat

    Q J Exp Physiol Cogn Med Sci

    (1973)
  • RS Jones et al.

    Choleretic effects of cholecystokinin, gastrin II, and caerulein in the dog

    Am J Physiol

    (1970)
  • MA Ondetti et al.

    Cholecystokinin-pancreozymin: recent developments

    Am J Dig Dis

    (1970)
  • Cited by (149)

    • Drug Transport—Uptake

      2022, Comprehensive Pharmacology
    • Differences in transport function of the human and rat orthologue of the Organic Anion Transporting Polypeptide 2B1 (OATP2B1)

      2021, Drug Metabolism and Pharmacokinetics
      Citation Excerpt :

      Differences in substrate recognition of closely related OATP family members are well-known. One example are the liver-enriched transporters OATP1B1 and OATP1B3, which exhibit a broad substrate overlap [46], but transport of cholecystokinin 8 (CCK-8) is a unique feature of OATP1B3 [47], while transport of E1S is only mediated by OATP1B1 [48]. Testing the influence of amino acid exchanges revealed that non-conserved amino acid residues in TMD-1, TMD-10, and the ECL-6 are relevant for CCK-8 substrate recognition [56].

    • Elucidation of OATP1B1 and 1B3 transporter function using transgenic rodent models and commonly known single nucleotide polymorphisms

      2020, Toxicology and Applied Pharmacology
      Citation Excerpt :

      However, the mechanism remains to be understood. Although CCK-8 has no metabolic impact on hepatocytes, it is efficiently taken up from the portal blood into the liver where it is rapidly metabolized and excreted (Ismair et al., 2001). Studies on the uptake of CCK-8 in Xenopus oocytes expressing four organic anion-transporting polypeptides of rat liver and of human liver as well as in primary cultured rat hepatocytes showed that CCK-8 is selectively transported by rat Oatp1b2 (Oatp4) and human OATP1B3 (OATP8), with Km values of 14.9 ± 2.9 μM and 11.1 ± 2.9 μM, respectively (Ismair et al., 2001).

    View all citing articles on Scopus

    Address requests for reprints to: Gerd A. Kullak-Ublick, M.D., Division of Clinical Pharmacology and Toxicology, Department of Medicine, University Hospital, CH-8091 Zurich, Switzerland. e-mail: [email protected]; fax: (41) 1-255-4411.

    ☆☆

    Supported by grant 32-59155.99 from the Swiss National Science Foundation, Bern, Switzerland.

    View full text